🩹 Category
Peptides for Healing & Recovery
Peptides investigated for tissue repair — tendons, ligaments, muscle, and the gut lining. Largely animal research.
Peptides investigated for tissue repair — tendons, ligaments, muscle, and the gut lining. Largely animal research.
Healing and recovery peptides are studied for their effects on tissue repair — tendons, ligaments, muscle, the gut lining, and bone. This category mixes two very different worlds. On one side are popular "research chemicals" like BPC-157 and TB-500, hugely popular in fitness circles but supported almost entirely by animal studies, with no completed human trials. On the other are genuinely approved peptide medicines for specific repair-related conditions.
Among the approved drugs here: teduglutide (a GLP-2 analog that regrows intestinal lining in short bowel syndrome) and the bone-building osteoporosis agents teriparatide and abaloparatide. Reading these pages side by side is a useful lesson in the gap between a compound that "works in mice" and one proven in people.
A synthetic peptide fragment that has become one of the most studied “healing” peptides in animal research, though it has not completed human clinical trials.
Read the guide →A synthetic peptide related to Thymosin Beta-4, an actin-binding protein involved in cell migration and tissue repair.
Read the guide →A naturally occurring copper-binding tripeptide that declines with age and is widely used in cosmetic skincare for its collagen and skin-repair signaling.
Read the guide →The body's main cathelicidin antimicrobial peptide, central to innate immunity and wound healing — but with a complex, context-dependent (and sometimes harmful) biology.
Read the guide →A tripeptide fragment of α-MSH studied for anti-inflammatory effects, particularly in the gut and skin, without α-MSH's pigmentation activity.
Read the guide →The full naturally occurring 43-amino-acid protein that regulates actin and tissue repair — the parent molecule that the popular “TB-500” is a fragment/analog of.
Read the guide →A peptide derived from the tissue-protective region of erythropoietin (EPO) — without EPO's red-blood-cell effects — studied in trials for neuropathic pain and small-fiber neuropathy.
Read the guide →An oral peptide that regulates intestinal tight junctions (“leaky gut”), studied most for celiac disease — it reached Phase 3, though that trial did not meet its primary endpoint.
Read the guide →A GLP-2 receptor agonist and FDA-approved drug (Gattex) that promotes intestinal growth and absorption in people with short bowel syndrome.
Read the guide →A recombinant fragment of parathyroid hormone (PTH 1–34) and FDA-approved anabolic drug (Forteo) that builds new bone in people with osteoporosis at high fracture risk.
Read the guide →A PTH-related protein analog and FDA-approved anabolic drug (Tymlos) that stimulates new bone formation in people with osteoporosis at high fracture risk.
Read the guide →A minimally absorbed guanylate cyclase-C agonist peptide, FDA-approved (as Linzess) for irritable bowel syndrome with constipation and chronic idiopathic constipation.
Read the guide →A guanylate cyclase-C agonist peptide (Trulance), FDA-approved for chronic idiopathic constipation and IBS with constipation, designed to mimic the natural hormone uroguanylin.
Read the guide →A peptide hormone that lowers blood calcium and slows bone breakdown; the salmon form (Miacalcin, Fortical) is FDA-approved for osteoporosis, Paget's disease, and hypercalcemia.
Read the guide →A gastrointestinal hormone, available as a diagnostic agent (ChiRhoStim), used to assess pancreatic function and gastrin-secreting tumors — and famously studied, then refuted, as an autism treatment.
Read the guide →The compounds in this category are grouped by an intended outcome — faster tissue repair — rather than by a shared mechanism, so the proposed pathways vary considerably.
Angiogenesis and growth-factor signalling. BPC-157 is described in the animal literature as promoting new blood-vessel formation and interacting with growth-factor pathways involved in repair. Blood supply is the rate-limiting factor in healing tissues like tendon and ligament, so a compound that improved it would matter.
Cell migration and cytoskeletal remodelling. TB-500 and thymosin beta-4 act on actin, the protein scaffolding cells use to move. Repair depends on cells migrating into damaged tissue, which is the rationale for this approach.
Copper transport and collagen synthesis. GHK-Cu binds copper, a cofactor in collagen cross-linking and several repair enzymes, and has the most substantial cosmetic-science literature of anything in this group.
Approved gut and bone medicines. This category also holds genuine prescription drugs — teduglutide for short bowel syndrome, linaclotide and plecanatide for constipation disorders, teriparatide and abaloparatide for osteoporosis. These have defined indications and real trial data.
Healing peptides are where the distance between preclinical enthusiasm and human evidence is largest, and it is the single most important thing to understand about this category.
The rodent literature on BPC-157 is genuinely extensive: accelerated healing of tendon, muscle, ligament, gut and nerve injuries across a range of models, with plausible mechanistic work behind it. Similar preclinical results exist for TB-500.
There are no completed randomized controlled trials in humans for either compound, for any injury. No efficacy data, no dose-finding, no controlled safety data, no imaging outcomes. Every human claim in circulation is either extrapolated from rodents or anecdotal.
Two things make that gap harder to bridge than it looks. Rodent studies typically use acute surgical injuries, whereas the chronic degenerative tendon problems people actually have are a different pathology. And soft-tissue injuries frequently improve on their own over exactly the timeframe someone would be taking a repair peptide — meaning personal experience cannot distinguish the compound from ordinary recovery.
None of this makes the research uninteresting. It makes it research. See peptides for tendon repair and do peptides actually work? for the longer version.
BPC-157 shows tendon, gut and soft-tissue healing in rodent studies, but there are no completed published human clinical trials, so its effectiveness and safety in people remain unproven. It is also not FDA-approved and is banned in sport.
They are different molecules: BPC-157 derives from a stomach protein and is studied mostly for tendon and gut healing, while TB-500 is a fragment of the actin-regulating protein Thymosin Beta-4 studied for cell migration and broad tissue repair. Neither is approved.
Yes — for specific conditions. Teduglutide is approved for short bowel syndrome, and teriparatide and abaloparatide are approved anabolic (bone-building) drugs for osteoporosis. These are prescription medicines, unlike the unapproved 'recovery' research chemicals.